Drägerwerk AG & Co. KGaA (LON:0MT8)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 1.23B +41.9% |
| Revenue (ttm) | 3.06B +4.2% |
| Net Income | 133.61M +32.8% |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | 9.19 |
| Forward PE | 9.56 |
| Dividend | 1.91 (2.73%) |
| Ex-Dividend Date | May 11, 2026 |
| Volume | 134 |
| Average Volume | 96 |
| Open | 68.00 |
| Previous Close | 69.00 |
| Day's Range | 66.60 - 68.00 |
| 52-Week Range | 48.70 - 77.40 |
| Beta | 0.56 |
| RSI | 43.36 |
| Earnings Date | Apr 30, 2026 |
About Drägerwerk AG & Co. KGaA
Drägerwerk AG & Co. KGaA operates as a medical and safety technology company worldwide. It develops, produces, and markets system solutions, devices, and services for the medical division, including emergency medicine, perioperative care, intensive care, and perinatal medicine. The company also develops, produces, and markets products, system solutions, and services for personal protection, gas measurement technology, and comprehensive risk management to customers in industry and mining sectors, as well as public sectors, such as fire departmen... [Read more]
Financial Performance
In 2025, Drägerwerk AG & Co. KGaA's revenue was 3.48 billion, an increase of 3.29% compared to the previous year's 3.37 billion. Earnings were 139.50 million, an increase of 12.13%.
Financial numbers in EUR Financial StatementsNews
Drägerwerk AG & Co. KGaA Earnings Call Transcript: Q1 2026
EBIT and Free Cash Flow rose sharply in Q1 2026, with strong sales growth and improved margins. Both divisions contributed to higher earnings, and guidance for the year remains positive, with no material impact expected from tariffs or geopolitical risks.
Drägerwerk Q1 2026 Earnings Soar Beyond Expectations
Preliminary Q1 2026 figures point to solid top-line growth, stronger profitability and robust order intake, while the full-year outlook remains unchanged.
EQS-Adhoc: Correction of a release from 16/04/2026, 19:17 CET/CEST - Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
EQS-Ad-hoc: Drägerwerk AG & Co. KGaA / Key word(s): Results / Quarter/Forecast / Full year Correction of a release from 16/04/2026, 19:17 CET/CEST - Drägerwerk AG & Co. KGaA: Preliminary figures Q1 20...
Drägerwerk Q1 2026: Earnings Significantly Up from Last Year!
Dräger starts 2026 with solid momentum: rising sales, stronger margins and robust order intake signal a year of profitable, broad-based growth ahead.
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
EQS-Ad-hoc: Drägerwerk AG & Co. KGaA / Key word(s): Results / Quarter/Forecast / Full year Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year 16-Apr-2026 / ...
Drägerwerk AG & Co. KGaA Transcript: German Select VII Conference
The company reported record sales and margin growth in 2025, driven by strong operational performance and innovation in open medical ecosystems. Defense and Safety segments are set for significant expansion, while margin improvement will rely on top-line growth, pricing, and cost control.
Drägerwerk AG & Co: Online-Präsentation German Select 7 Conference am 14.04.2026
Drägerwerk AG & Co. KGaA: Online-Präsentation German Select 7 Conference am 14.04.2026